ArticleLancet regional health. Americas2024

Safety of SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 receptor agonists in US veterans with and without chronic kidney disease: a population-based study.

Yoko Narasaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.